These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 12389305)

  • 1. [Anti-varicella vaccine: immunogenicity, efficacy, and safety].
    Principi N
    Ann Ig; 2002; 14(4 Suppl 6):51-4. PubMed ID: 12389305
    [No Abstract]   [Full Text] [Related]  

  • 2. [Target of the anti-varicella vaccine].
    Germinario C; Lopalco PL; Prato R; Quarto M
    Ann Ig; 2002; 14(4 Suppl 6):55-8. PubMed ID: 12389306
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1.
    Armenian SH; Han JY; Dunaway TM; Church JA
    Pediatr Infect Dis J; 2006 Apr; 25(4):368-70. PubMed ID: 16567993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varicella immunization and herpes zoster.
    Volpi A
    Herpes; 2005 Dec; 12(3):59. PubMed ID: 16393520
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.
    Leung TF; Li CK; Hung EC; Chan PK; Mo CW; Wong RP; Chik KW
    Eur J Haematol; 2004 May; 72(5):353-7. PubMed ID: 15059071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varicella vaccination in Australia.
    Macartney KK; Beutels P; McIntyre P; Burgess MA
    J Paediatr Child Health; 2005 Nov; 41(11):544-52. PubMed ID: 16398834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varicella vaccine update: need for a booster?
    Hoey J
    CMAJ; 2003 Mar; 168(5):589. PubMed ID: 12615756
    [No Abstract]   [Full Text] [Related]  

  • 8. [Anti-varicella vaccination program in the United States of America].
    D'Alessandro D; Valle S
    Ann Ig; 2002; 14(4 Suppl 6):59-65. PubMed ID: 12389307
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Varicella vaccine].
    Abarca Villaseca K
    Rev Chilena Infectol; 2006 Mar; 23(1):56-9. PubMed ID: 16462966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan.
    Ozaki T; Nishimura N; Muto T; Sugata K; Kawabe S; Goto K; Koyama K; Fujita H; Takahashi Y; Akiyama M
    Vaccine; 2005 Jan; 23(10):1205-8. PubMed ID: 15652662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varicella virus vaccine before pregnancy. Important breakthrough in protecting fetuses.
    Koren G
    Can Fam Physician; 2000 Oct; 46():1975-7. PubMed ID: 11072577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.
    Diaz C; Dentico P; Gonzalez R; Mendez RG; Cinquetti S; Barben JL; Harmon A; Chalikonda I; Smith JG; Stek JE; Robertson A; Caulfield MJ; Biasio LR; Silber JL; Chan CY; Vessey R; Sadoff J; Chan IS; Matthews H; Wang W; Schlienger K; Schödel FP;
    Vaccine; 2006 Nov; 24(47-48):6875-85. PubMed ID: 17050042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing varicella vaccine efficacy.
    Wood J; MacIntyre R; Macartney K
    Pediatr Infect Dis J; 2008 Feb; 27(2):190; author reply 190-1. PubMed ID: 18174858
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary transmission of varicella vaccine virus in a chronic care facility for children.
    Grossberg R; Harpaz R; Rubtcova E; Loparev V; Seward JF; Schmid DS
    J Pediatr; 2006 Jun; 148(6):842-4. PubMed ID: 16769402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.
    Levin MJ; Gershon AA; Weinberg A; Song LY; Fentin T; Nowak B;
    J Infect Dis; 2006 Jul; 194(2):247-55. PubMed ID: 16779732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2007 Jul; 120(1):221-31. PubMed ID: 17606582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention strategies: experience of varicella vaccination programmes.
    Patrick D
    Herpes; 2007 Sep; 14 Suppl 2():48-51. PubMed ID: 17939897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.